FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:2602-2604 December 15, 2005 Number 24 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article Related Article by Sánchez-Guerrero, J. Related Article by Petri, M. PubMed Citation

Oral contraceptives were introduced into clinical practice in the 1960s. The "pill," as this method of contraception was quickly dubbed, was touted for its ease of administration and effectiveness. The subsequent wide use of oral contraceptives provided women with invaluable reproductive choices and social opportunities.¹ As a result, the pill has been called one of the most socially important advances of the modern medical era.² Yet for patients with systemic lupus erythematosus, there has been an implicit moratorium on prescribing these medications because of concerns that exogenous estrogens could potentially exacerbate disease symptoms.

The large ratio of women to men . . . [Full Text of this Article]

Source Information

From the Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston.

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.